VACCINE DELIVERY
Mucosal vaccines eliciting 100% sterilizing immunity agaoinst respiratory viruses
Why NovochizolTM ?
- Capacity to formulate all classes of vaccines: proteins, nucleic acids, viruses and virus-like particles
- Protection of antigens against degradation in extracellular environments
- Endocytosis of Novochizol::antigen complexes leading to increase in antigen presentation on APC cells
- For injectable vaccines: bioadhesion to tissues for prolonged and sustained antigen exposure to sentinel cells
- For mucosal vaccines: strong mucoadhesion, decreasing mucociliary clearance
- For mucosal vaccines: ability to open tight junctions between epithelial cells of the mucosae
- Chitosan-mediated enhancement of overall immune responses.
Research and Development
Novochizol™ hemagglutinin intranasal vaccine with 100% efficacy
BALB/c mice were vaccinated against H5NB either through intramuscular injection with H5 hemagglutinin with aluminum hydroxide ( IM group) or via intranasal administration of a Novochizol-based H5 formulation ( IN group). Upon exposure to live H5N8, mice in the IM group developed high blood titers of specific antibodies (blood titer: 13770) with 90% survival, but mice in the IN group developed low blood titers of specific antibodies (blood titer: 1778) with 100% survival.
Novochizol™: an effective adjuvant for intramuscular vaccines
BALB/c mice were vaccinated against H5NB through intramuscular injection of H5 + Seppic ISA 70 (S group) or of a Novochizol-based H5 formulation ( N group). Total blood titers of specific antibodies in the N group were equal or superior to that of the S group.
Novochizol™ protects labile proteins from degradation
In the context of a collaborative research project with the EPFL on the formulation of anti-cancer immunotherapies we have demonstrated that interleukin-2, a labile cytokine with a half -life of less than 5 minutes in vivo, retained its biological activity in vitro when formulated with Novochizol™ for at least 6 weeks. Extended preservations and protection were also observed with Botulinum toxin in vitro and in vivo and with poly-Arginine in vivo.
Novochizol™ -based vaccines elisit immunity regardless of route of administration
Recombinant Influenza A/H5 hemagglutinin formulated with Novochizol™ was administered either via intramuscular injection (IM) or intranasally (IN) to BALB/c mice. After 2 immunizations, specific antibodies were detected in the blood in both the IM group ( blood titer: 26730) and the IN group ( blood titer: 13770).
